Trials / Completed
CompletedNCT02346578
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Taro Iguchi, MD, PHD · Academic / Other
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to compare the efficacy and safety of enzalutamide or alternative AA therapy in CRPC participants who were previously treated with a combined androgen blockade therapy which included bicalutamide (Bic-CAB). Efficacy and safety of enzalutamide and alternative AA therapy will be evaluated, and effective therapy against CRPC after treatment with Bic-CAB will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | |
| DRUG | Flutamide |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-09-30
- Completion
- 2019-01-22
- First posted
- 2015-01-27
- Last updated
- 2021-09-16
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02346578. Inclusion in this directory is not an endorsement.